Literature DB >> 12510879

Discriminant and quantitative PLS analysis of competitive CYP2C9 inhibitors versus non-inhibitors using alignment independent GRIND descriptors.

Lovisa Afzelius1, Collen M Masimirembwa, Anders Karlén, Tommy B Andersson, Ismael Zamora.   

Abstract

This study describes the use of alignment-independent descriptors for obtaining qualitative and quantitative predictions of the competitive inhibition of CYP2C9 on a serie of highly structurally diverse compounds. This was accomplished by calculating alignment independent descriptors in ALMOND. These GRid INdependent Descriptors (GRIND) represent the most important GRID-interactions as a function of the distance instead of the actual position of each grid-point. The experimental data was determined under uniform conditions. The inhibitor data set consists of 35 structurally diverse competitive stereospecific inhibitors of the cytochrome P450 2C9 and the non -inhibitor data set of 46 compounds. In a PLS discriminant analysis 21 inhibitors and 21 non-inhibitors (1 and 0 as activities) were analyzed using the ALMOND program obtaining a model with an r2 of 0.74 and a cross-validation value (q2) of 0.64. The model was externally validated with 39 compounds (14 inhibitors/25 non-inhibitors). 74% of the compounds were correctly predicted and an additional 13% was assigned to a borderline cluster. Thereafter, a model for quantitative predictions was generated by a PLS analysis of the GRIND descriptors using the experimental Ki-value for 21 of the competitive inhibitors (r2 = 0.77, q2 = 0.60). The model was externally validated using 12 compounds and predicted 11 out of 12 of the Ki-values within 0.5 log units. The discriminant model will be useful in screening for CYP2C9 inhibitors from large compound collections. The 3D-QSAR model will be used during lead optimization to avoid chemistry that result in inhibition of CYP2C9.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12510879     DOI: 10.1023/a:1021281008423

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  19 in total

1.  Heterologous expression and kinetic characterization of human cytochromes P-450: validation of a pharmaceutical tool for drug metabolism research.

Authors:  C M Masimirembwa; C Otter; M Berg; M Jönsson; B Leidvik; E Jonsson; T Johansson; A Bäckman; A Edlund; T B Andersson
Journal:  Drug Metab Dispos       Date:  1999-10       Impact factor: 3.922

2.  VolSurf: a new tool for the pharmacokinetic optimization of lead compounds.

Authors:  G Cruciani; M Pastor; W Guba
Journal:  Eur J Pharm Sci       Date:  2000-10       Impact factor: 4.384

3.  GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors.

Authors:  M Pastor; G Cruciani; I McLay; S Pickett; S Clementi
Journal:  J Med Chem       Date:  2000-08-24       Impact factor: 7.446

4.  Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9.

Authors:  J P Jones; M He; W F Trager; A E Rettie
Journal:  Drug Metab Dispos       Date:  1996-01       Impact factor: 3.922

Review 5.  Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites.

Authors:  S Ekins; M J de Groot; J P Jones
Journal:  Drug Metab Dispos       Date:  2001-07       Impact factor: 3.922

6.  Comparative molecular field analysis using GRID force-field and GOLPE variable selection methods in a study of inhibitors of glycogen phosphorylase b.

Authors:  G Cruciani; K A Watson
Journal:  J Med Chem       Date:  1994-08-05       Impact factor: 7.446

7.  A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions.

Authors:  S Rao; R Aoyama; M Schrag; W F Trager; A Rettie; J P Jones
Journal:  J Med Chem       Date:  2000-07-27       Impact factor: 7.446

8.  Synthesis and comparative molecular field analysis (CoMFA) of symmetric and nonsymmetric cyclic sulfamide HIV-1 protease inhibitors.

Authors:  W Schaal; A Karlsson; G Ahlsén; J Lindberg; H O Andersson; U H Danielson; B Classon; T Unge; B Samuelsson; J Hultén; A Hallberg; A Karlén
Journal:  J Med Chem       Date:  2001-01-18       Impact factor: 7.446

Review 9.  Mechanisms and significance of inhibitory drug interactions involving cytochrome P450 enzymes (review).

Authors:  M Murray
Journal:  Int J Mol Med       Date:  1999-03       Impact factor: 4.101

10.  A fast new approach to pharmacophore mapping and its application to dopaminergic and benzodiazepine agonists.

Authors:  Y C Martin; M G Bures; E A Danaher; J DeLazzer; I Lico; P A Pavlik
Journal:  J Comput Aided Mol Des       Date:  1993-02       Impact factor: 3.686

View more
  4 in total

1.  Use of alignment-free molecular descriptors in diversity analysis and optimal sampling of molecular libraries.

Authors:  Fabien Fontaine; Manuel Pastor; Hugo Gutiérrez-de-Terán; Juan J Lozano; Ferran Sanz
Journal:  Mol Divers       Date:  2003       Impact factor: 2.943

Review 2.  Modeling kinetics of subcellular disposition of chemicals.

Authors:  Stefan Balaz
Journal:  Chem Rev       Date:  2009-05       Impact factor: 60.622

Review 3.  Structural features of cytochromes P450 and ligands that affect drug metabolism as revealed by X-ray crystallography and NMR.

Authors:  Sean C Gay; Arthur G Roberts; James R Halpert
Journal:  Future Med Chem       Date:  2010-09       Impact factor: 3.808

Review 4.  Computational prediction of metabolism: sites, products, SAR, P450 enzyme dynamics, and mechanisms.

Authors:  Johannes Kirchmair; Mark J Williamson; Jonathan D Tyzack; Lu Tan; Peter J Bond; Andreas Bender; Robert C Glen
Journal:  J Chem Inf Model       Date:  2012-02-17       Impact factor: 4.956

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.